New progress towards elimination of mother-to-child transmission of hepatitis B virus in China

Hepatol Int. 2022 Dec;16(6):1273-1281. doi: 10.1007/s12072-022-10400-0. Epub 2022 Oct 18.

Abstract

Background: We conducted an evaluation on the potential data resources for the elimination of hepatitis B virus (HBV) mother-to-child transmission in China, so as to provide reference for WHO and other countries in the validation of HBV elimination of mother-to-child transmission (EMTCT) in a real-world large country setting.

Methods: We used the indicators set out in WHO Interim guidance for country validation of viral hepatitis elimination as the benchmark to evaluate the availability of data and progress against indicators for the elimination validation in China. We used descriptive analysis to illustrate the status of all indicators and parameters.

Results: According to the indicators which are recommended by WHO for HBV EMTCT validation, the national data in China are attainable, though not for HBV DNA testing for the HBsAg-positive mothers and their subsequent management. The remaining challenges for China are to consider how the national serosurvey might be conducted in future in the context of low HBV prevalence among children under 5 years; to collect systematically the programmatic impact data; to strengthen multi-sectoral collaboration among immunization, maternal and child health, hospital services, as well as other stakeholders.

Conclusion: The available data on HBV EMTCT are sufficient to support the validation of the elimination of HBV mother-to-child transmission in China.

Keywords: China; Elimination of mother-to-child transmission; Hepatitis B; Validation.

MeSH terms

  • Child, Preschool
  • China / epidemiology
  • Female
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Hepatitis B virus / genetics
  • Hepatitis B* / epidemiology
  • Hepatitis B* / prevention & control
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical / prevention & control
  • Pregnancy
  • Pregnancy Complications, Infectious* / epidemiology
  • Pregnancy Complications, Infectious* / prevention & control

Substances

  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines